Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INCY – Incyte Corporation

Float Short %

3.85

Margin Of Safety %

10

Put/Call OI Ratio

0.65

EPS Next Q Diff

0.5

EPS Last/This Y

5.93

EPS This/Next Y

1.07

Price

85.04

Target Price

82.4

Analyst Recom

2.39

Performance Q

31.82

Relative Volume

0.79

Beta

0.74

Ticker: INCY




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25INCY70.180.581.8711315
2025-07-28INCY70.210.580.0311346
2025-07-29INCY77.40.450.4113376
2025-07-30INCY77.550.470.5214457
2025-07-31INCY74.90.471.4914576
2025-08-01INCY75.60.490.8814867
2025-08-04INCY78.060.490.0714842
2025-08-05INCY77.750.490.5414872
2025-08-06INCY77.650.480.0914771
2025-08-07INCY78.230.470.4014988
2025-08-08INCY78.420.470.0915052
2025-08-11INCY79.190.460.6315302
2025-08-12INCY81.640.460.0215387
2025-08-13INCY85.850.451.8215532
2025-08-14INCY86.160.591.2417418
2025-08-15INCY86.940.610.1617811
2025-08-18INCY84.920.690.1815979
2025-08-19INCY85.490.680.0716241
2025-08-20INCY86.180.660.0216428
2025-08-21INCY86.550.650.0516737
2025-08-22INCY85.050.650.1116722
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25INCY70.20177.1956.55.77
2025-07-28INCY70.16181.0962.05.83
2025-07-29INCY77.38181.01122.35.83
2025-07-30INCY77.55181.0967.95.83
2025-07-31INCY74.8953.4-36.96.18
2025-08-01INCY75.5953.4103.86.18
2025-08-04INCY78.0456.2140.96.23
2025-08-05INCY77.7256.282.16.23
2025-08-06INCY77.6856.287.66.08
2025-08-07INCY78.2056.2100.16.08
2025-08-08INCY78.3956.092.66.09
2025-08-11INCY79.2156.0105.46.09
2025-08-12INCY81.6156.0137.56.09
2025-08-13INCY85.8556.0171.46.09
2025-08-14INCY86.1656.094.46.09
2025-08-15INCY86.9356.0102.76.09
2025-08-18INCY84.9356.052.66.09
2025-08-19INCY85.4656.098.76.09
2025-08-20INCY86.1856.0102.06.09
2025-08-21INCY86.5556.095.16.09
2025-08-22INCY85.0456.061.66.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25INCY-3.085.673.73
2025-07-28INCY-3.086.043.73
2025-07-29INCY-3.086.043.73
2025-07-30INCY-3.086.043.73
2025-07-31INCY-3.086.043.73
2025-08-01INCY-3.056.043.70
2025-08-04INCY-3.055.533.70
2025-08-05INCY-3.055.533.70
2025-08-06INCY-3.075.533.70
2025-08-07INCY-3.075.533.70
2025-08-08INCY-3.075.533.70
2025-08-11INCY-3.075.573.70
2025-08-12INCY-3.075.573.86
2025-08-13INCY-3.075.573.86
2025-08-14INCY-3.075.573.86
2025-08-15INCY-3.075.573.86
2025-08-18INCY-3.074.563.86
2025-08-19INCY-3.084.563.85
2025-08-20INCY-3.584.563.85
2025-08-21INCY-3.584.563.85
2025-08-22INCY-3.584.563.85
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.31

Avg. EPS Est. Current Quarter

1.67

Avg. EPS Est. Next Quarter

1.81

Insider Transactions

-3.58

Institutional Transactions

4.56

Beta

0.74

Average Sales Estimate Current Quarter

1254

Average Sales Estimate Next Quarter

1315

Fair Value

93.54

Quality Score

100

Growth Score

90

Sentiment Score

88

Actual DrawDown %

16.2

Max Drawdown 5-Year %

-49.1

Target Price

82.4

P/E

19.33

Forward P/E

11.96

PEG

0.2

P/S

3.62

P/B

3.96

P/Free Cash Flow

17.33

EPS

4.4

Average EPS Est. Cur. Y​

6.09

EPS Next Y. (Est.)

7.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.99

Relative Volume

0.79

Return on Equity vs Sector %

-3.8

Return on Equity vs Industry %

9.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.32

EBIT Estimation

61.6
Incyte Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 2617
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
stock quote shares INCY – Incyte Corporation Stock Price stock today
news today INCY – Incyte Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch INCY – Incyte Corporation yahoo finance google finance
stock history INCY – Incyte Corporation invest stock market
stock prices INCY premarket after hours
ticker INCY fair value insiders trading